PATENT CLAIM ANALYSIS

Application Number: 16130817
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["540", "521000"]

Abstract:
The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Claim (Index 1):
A compound of Formula I: wherein R 1  is H or optionally substituted C 1 -C 6  alkyl; together form an optionally substituted aryl or optionally substituted heteroaryl of formula: Y 1  is O or NR 2 , where R 2  and R 1  together with the nitrogen atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring; Y 2  is \u2014O\u2014, \u2014S\u2014, \u2014S(O)\u2014, \u2014S(O) 2 \u2014, \u2014S(O)(NH)\u2014, \u2014NR 5 \u2014 or \u2014C(R 6 ) 2 \u2014; R 5  is H or optionally substituted C 1 -C 6  alkyl; each R 6  is independently H, halo, optionally substituted C 1 -C 6  alkyl, or two R 6  together with the carbon atom to which they are attached, form a C 1 -C 6  alken-1-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; R 3  and R 4  are independently H, halo, optionally substituted C 1 -C 6  alkyl, R 3  and R 4  together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R 3  and R 6  together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring; L is absent, \u2014O\u2014, \u2014S\u2014, \u2014S(O)\u2014, \u2014S(O) 2 \u2014, \u2014NR 7 \u2014 or \u2014C(R 8 ) 2 \u2014; R 7  is H or optionally substituted C 1 -C 6  alkyl; each R 8  is independently H, halo, optionally substituted C 1 -C 6  alkyl, or two R 8  together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and R 9  is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; provided that at least one of the following occurs: (1) at least one of R 3  and R 4  are halo or optionally substituted C 1 -C 6  alkyl, R 3  and R 4  together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R 3  and R 6  together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; (2) L is absent or \u2014C(R 8 ) 2 \u2014, and each R 8  is optionally substituted C 1 -C 6  alkyl or halo provided that the compound is not 5-(difluoro(phenyl)methyl)-N-(4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)isoxazole-3-carboxamide or not 5-(difluoro(phenyl)methyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)isoxazole-3-carboxamide or two R 8  together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; (3) Y 1  is NR 2 ; Y 2  is \u2014O\u2014; and A is substituted with halo or cyano; or A is thiazolyl or a 3- or 4-membered ring; provided that the compound is not 2-(4-bromobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)thiazole-4-carboxamide or 2-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)thiazole-4-carboxamide; (6) Y 2  is \u2014S\u2014, \u2014S(O)\u2014, or \u2014S(O) 2 \u2014; and A is other than 1,3-isoxazole or Y 2  is \u2014S(O)(NH)\u2014; (7) Y 2  is \u2014NR 5 \u2014; X 1  and X 2  together form an optionally substituted phenyl, and A is other than isoxazole, pyrazole and triazole; X 1  and X 2  together form an optionally substituted pyridyl, and A is other than triazole; or X 1  and X 2  are optionally substituted pyrimidyl, and A is other than pyrazole and triazole; or (8) the carbonyl moiety and L are substituted other than 1,3-on ring A; or a pharmaceutically acceptable salt, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 97.0
- Lexical Diversity: 1.0625
- Patent Class: 540.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15424216', '15721470', '15721419', '15459141', '11925151']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7053903714698576
- 35 USC 102 Novelty (BERT): 0.571557773180879
- Combined Prediction Score: 0.6920071116409597
- Mean Citation Score: 361.03180000000015
- Max Citation Score: 460.94983
- Similarity Product: 337.3013621656942

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test